#Italy #Milan #Chronic Disease #Sinocare #EASD

Sinocare Unveils Comprehensive Chronic Disease Management Solutions at EASD 2026

Sinocare, a leading player in diabetes management technologies, showcased its extensive range of integrated solutions for chronic disease management during the 62nd annual meeting of the European Association for the Study of Diabetes (EASD 2026) held in Milan from September 28 to October 2, 2026. This comprehensive portfolio is designed for use across various settings, including home care, community pharmacies, and hospital environments. It addresses essential aspects of chronic disease management—from risk screening and daily monitoring to clinical evaluations and patient care.

Innovative Home Care Solutions

In the realm of home healthcare, Sinocare introduced the Safe AQ Max II Blood Glucose Monitoring System, which delivers results in just five seconds, supporting data synchronization via Bluetooth, along with pre- and post-meal marking. Additionally, their KUG-11 meter facilitates three metabolic analyses within a single device, while the GV-100 Veterinary Blood Glucose Monitoring System enables diabetes management for pets, such as dogs and cats, at home. These tools are pivotal for both patients and caregivers, ensuring effective monitoring of glucose levels and overall metabolic health.

Advancements for Community Pharmacies

For community pharmacies, the introduction of the iCARE-1300 Portable Automatic Multifunction Analyzer marks a significant step forward. This device can quickly analyze nearly 100 different parameters, including blood glucose, lipid profiles, HbA1c, and kidney function, yielding results in approximately 3 to 15 minutes. Sinocare's "Health Station" model enhances pharmacies' capabilities in chronic disease screening and risk assessment, making them a vital resource for local communities.

Hospital Solutions

In the hospital setting, Sinocare’s AGEscan Advanced Glycation End Products Fluorescence Detector stands out as a non-invasive tool for early risk detection of chronic diseases without requiring blood samples. Moreover, the Safe AQ 8000 Hospital Blood Glucose Smart Management System integrates seamlessly with hospital information systems (HIS), allowing for comprehensive management of glucose and continuous glucose monitoring (CGM) data through a user-friendly web portal for healthcare professionals. This not only enhances the quality of care provided to patients but also streamlines the overall management of diabetes within the hospital.

A Unified Approach to Chronic Disease Management

Together, these solutions illustrate Sinocare's commitment to connect screening, monitoring, and long-term management in various care environments. Sinocare aims to push the boundaries of biosensing technology and integrated health solutions, making chronic disease management more accessible and interconnected on a global scale. Founded in 2002, Sinocare is the first Chinese company to be publicly listed in the blood glucose meter space and is recognized as the largest manufacturer of blood glucose monitoring devices in the country. With over 780 patents and research and production facilities across the globe, Sinocare serves more than 25 million users in 187 countries, standing among the top four global manufacturers of blood glucose meters. Adopting a "Biosensing + AI + Health" approach, the company develops products and solutions for chronic disease screening, monitoring, and long-term management. For more information about Sinocare and its offerings, visit their website at www.sinocare.com/en.